---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-082266"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2022-07-25T23:59:59+00:00"
generated_at: "2026-06-24T09:15:29.166572+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharmaceuticals raises $4.225M in registered direct offering; reports $9.1M cash

## Summary
- Gross proceeds of ~$4.225M from sale of 1,289,980 shares/pre-funded warrants at $3.25 (institutional) and $3.80 (executives).
- Concurrent private placement of Series A and B warrants to purchase up to 1,289,980 shares each; exercisable starting 6 months.
- Preliminary cash and equivalents $9.1M as of June 30, 2022 (unaudited).
- Board granted one-time waiver of Insider Trading Policy to let CEO, Executive Chairman, and director participate in the offering.
- Net proceeds for general corporate purposes; closing expected July 27, 2022.

## SEC filing metadata
- accession: 0001104659-22-082266
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2022-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 5.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/0001104659-22-082266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-082266
- JSON: https://secwatch.observer/filing/0001104659-22-082266.json
- Plain text: https://secwatch.observer/filing/0001104659-22-082266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.